SCHEMBL6397474

SCHEMBL6397474

O=C(Nc1ccc(C2(O)CN(C(=O)OCc3ccccc3)C2)c(F)c1)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.49
TP53 P04637 2/20 0.48
MAPT P10636 2/20 0.48
NPC1 O15118 1/20 0.48
ALDH1A1 P00352 1/20 0.48
TSHR P16473 1/20 0.48
RAB9A P51151 1/20 0.48
ATM Q13315 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MGLL Q99685 3/20 0.47
PTGDR2 Q9Y5Y4 1/20 0.45
PTPN1 P18031 1/20 0.44
POLB P06746 1/20 0.44
KDM1A O60341 2/20 0.43
MAOA P21397 2/20 0.43
MAOB P27338 2/20 0.43
ENPP2 Q13822 2/20 0.43
ROCK2 O75116 1/20 0.43
RCOR1 Q9UKL0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6402241 0.90 TSHR (0.44) BTKTP53MAPTNPC1ALDH1A1
SCHEMBL6399505 0.90 MCHR1 (0.47) TP53MAPTNPC1ALDH1A1TSHR
SCHEMBL6401881 0.89 TSHR (0.47) TP53MAPTNPC1ALDH1A1TSHR
SCHEMBL6397390 0.85 NPC1 (0.46) BTKTP53MAPTNPC1ALDH1A1
SCHEMBL6398417 0.84 MCHR1 (0.47) TP53MAPTNPC1ALDH1A1TSHR
SCHEMBL1498503 0.78 MAPT (0.53) TP53MAPTNPC1ALDH1A1TSHR
SCHEMBL6399085 0.78 MGLL (0.51) TP53MAPTNPC1ALDH1A1TSHR
SCHEMBL6610001 0.78 TP53 (0.51) BTKTP53MAPTNPC1ALDH1A1
SCHEMBL18360183 0.77 PTGDR2 (0.45) NPC1ALDH1A1RAB9ASMN1; SMN2PTGDR2
SCHEMBL14168649 0.76 TP53 (0.47) TP53MAPTNPC1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050054683-A1 Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings HUTCHINSON DOUGLAS K (US) 2005-03-10 US disclosed
US-6358942-B1 MICROBIOCIDES AND BACTERICIDES FOR TREATING GRAMPOSITIVE, BACTEROIDES, CLOSTRIDIUM, MYCOBACTERIUM, STAPHYLOCOCCUS AND STREPTOCOCCUS INFECTIONS PHARMACIA & UPJOHN COMPANY 2002-03-19 US disclosed
US-6313307-B1 DEBLOCKING, DEPROTECTING; CATALYTIC HYDROGENATION, ALKYLATION; PREPARING MICROBIOCIDES AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, MYCOBACTERIUM, AND CLOSTRIDIUM PHARMACIA & UPJOHN COMPANY 2001-11-06 US disclosed
EP-0856002-B1 PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS UPJOHN CO (US) 2001-10-24 EP disclosed
US-6166056-A Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings PHARMACIA (US) 2000-12-26 US disclosed
US-6051716-A ANTIMICROBIAL AGENTS PHARMACIA & UPJOHN, INC. (US) 2000-04-18 US disclosed
US-6043266-A MICROBIOCIDES TREATING GRAM-POSITIVE BACTERIA INFECTIONS AND PERSONS WITH AIDS PHARMACIA & UPJOHN COMPANY (US) 2000-03-28 US disclosed
US-5968962-A ANTIMICROBIAL AGENTS; EFFECTIVE AGAINST GRAMPOSITIVE BACTERIA PHARMACIA & UPJOHN COMPANY (US) 1999-10-19 US disclosed
EP-0856002-A1 PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS PHARMACIA & UPJOHN COMPANY (US) 1998-08-05 EP disclosed
WO-1997009328-A1 PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS PHARMACIA & UPJOHN COMPANY (US) 1997-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054683-A1 Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings CBR1, NCOR1, RCOR1 BTK 2206/4885TP53 4315/4885MAPT 4365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.